缺口配体Dll4和Jagged1对血管生成有相反的影响
Rui Benedito1, Cristina Roca, Inga Sörensen
1Cancer Research UK London Research Institute, Vascular Development Laboratory, London, UK.
Cell
|June 16, 2009
概括
诺奇通路调节血管的生长. Jagged1对抗Dll4-Notch信号,通过平衡连接体相互作用来控制血管生成,这种机制可能对其他生物过程至关重要.
科学领域:
- 分子生物学分子生物学
- 发展生物学 发展生物学
- 细胞信号传递 细胞信号传递
背景情况:
- 切口通路对于细胞分化和组织模式至关重要.
- 突信号传递,由德尔塔样4 (Dll4) 介导,通常会抑制内皮细胞尖端细胞在血管生长中芽.
- 了解Notch信号的调节是控制血管生成的关键.
研究的目的:
- 为了研究诺奇带Jagged1在血管生成中的作用.
- 阐明Jagged1调节Dll4-Notch信号的机制.
- 为了确定Notch配体的平衡如何影响血管形成.
主要方法:
- 在小鼠体内体内的研究.
- 对诺奇受体糖化酶的分析.
- 在内皮细胞中对联体受体相互作用的研究.
- 对Jagged1和Dll4信号能力的比较评估.
主要成果:
- 在小鼠中,Jagged1充当了益血管性调节剂.
- 在细胞中,Jagged1通过边缘糖系转移酶对抗Dll4-Notch信号传递.
- 糖化增强了Dll4-Notch信号,而Jagged1与Dll4竞争,显示出较弱的信号.
- 在Jagged1和Dll4之间的平衡控制了血管生成.
结论:
- 诺奇配体Jagged1和Dll4之间的平衡,具有对立的角色和独特的表达模式,是血管生成的关键调节者.
- 这种涉及连接体竞争和糖化酶的调节机制可能扩展到由Notch路径控制的其他生物过程.
更多相关视频
08:16High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model
Published on: March 16, 2022
3.1K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.1K
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.8K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K